Long-noncoding RNA LINC00461 promotes proliferation and invasion of nonsmall cell lung cancer cells via targeting miR-518a-3p/WDR1 pathway

Emerging role of LINC00461 in cancer

LINC00461 is located in the intergenic region between the protein-coding genes MEF2C and TMEM161B. LINC00461 upregulation was associated with the risk of 13 tumors and was strongly associated with clinicopathologic features and poor prognosis in 11 tumors. LINC00461 is involved in resistance to four anticancer drugs, including sunitinib for renal cell carcinoma, cisplatin for head and neck squamous cell carcinoma and rectal cancer, temozolomide for glioma, and docetaxel for breast cancer. LINC00461 can sponge 18 miRNAs to form a complex ceRNA network that regulates the expression of a large number of downstream genes. LINC00461 is involved in the MAPK/ERK signaling pathway and PI3K/AKT signaling pathway, thereby promoting tumorigenesis. Notably, knockdown of LINC00461 in exosomes antagonizes tumor cell proliferation in multiple myeloma. This article summarizes the diagnostic, prognostic, and therapeutic value of LINC00461 in various tumors, and systematically describes the ceRNA network and signaling pathways associated with LINC00461, providing potential directions for future LINC00461 research.

Long noncoding RNA NNT-AS1 inhibits IL-17-induced proliferation, migration, and invasion of gastric cancer cells by regulating miR-518a-3p

BACKGROUND

Interleukin 17 (IL-17) is a cytokine secreted in many cell types, which is related to the development of tumor cells. The expression of the long noncoding RNA (lncRNA) nicotinamide nucleotide transhydrogenase antisense RNA1 (NNT-AS1) is up-regulated in gastric cancer tissues. NNT-AS1 may inhibit the proliferation and invasion of gastric cancer cells and arrest cell cycle progression by reducing the expression of miR-363. The regulatory mechanism of NNT-AS1 and IL-17 on gastric cancer cells is still not completely clear.

AIM

To explore the molecular mechanism by which NNT-AS1 inhibits IL-17-induced proliferation, migration, and invasion of gastric cancer cells.

METHODS

IL-17 was used to treat gastric cancer AGS cells, and the cells were divided into Con group, IL-17 group, IL-17 + si-NC group, IL-17 + si-lncRNA NNT-AS1 group, IL-17 + si-lncRNA NNT-AS1 + anti-miR-NC group, and IL-17 + si-lncRNA NNT-AS1 + anti-miR-518a-3p group. Real-time fluorescence quantitative PCR (RT-qPCR) was used to detect miR-518a-3p and NNT-AS1 expression. Colony forming assay and Transwell assay were performed to detect AGS cell proliferation, migration, and invasion. Western blot was used to detect relevant protein expression. Dual luciferase assay was used to detect the relationship of miR-518a-3p and NNT-AS1.

RESULTS

Compared with the Con group, the number of cell colonies, the number of migrating cells, and the number of invasive cells in the IL-17 group increased, the expression of Ki-67, N-cadherin, and MMP2 proteins increased, the expression of E-cadherin protein decreased, the expression of NNT-AS1 increased, and the expression of miR-518a-3p decreased. Down-regulation of NNT-AS1 decreased the number of cell colonies formed, the number of migrating cells, and the number of invasive cells in gastric cancer cells treated with IL-17, decreased the expression of Ki-67, matrix metalloproteinase 2 (MMP2), and N-cadherin proteins, and increased the expression of E-cadherin protein. NNT-AS1 targets and regulates the expression of miR-518a-3p. Inhibition of miR-518a-3p can reverse the effect of down-regulation of NNT-AS1 on IL-17-induced proliferation, migration, and invasion of gastric cancer cells.

CONCLUSION

NNT-AS1 inhibits IL-17-induced gastric cancer cell proliferation, migration, and invasion possibly by regulating the expression of miR-518a-3p.

Silencing of lncRNA CRNDE attenuates nonsmall-cell lung cancer progression by mediating the miR-455-3p/HDAC2 axis

Nonsmall-cell lung carcinoma (NSCLC) is one of the deadliest malignancies in the world. LncRNAs are confirmed to be involved in the progression of NSCLC. Meanwhile, lncRNA CRNDE is known to be upregulated in NSCLC; however, the mechanism by which CRNDE regulates the tumourigenesis of NSCLC remains unclear. To test the function of CRNDE in NSCLC, cell proliferation, invasion, and migration were investigated by colony formation and Transwell assays, respectively. qPCR and Western blotting were applied to test gene and protein levels. In addition, the relationship among CRNDE, miR-455-3p, and HDAC2 was explored by dual-luciferase and RIP assays. The data revealed that the expression of CRNDE was upregulated in NSCLC tissues, while miR-455-3p was downregulated. CRNDE knockdown inhibited the viability, migration and invasion of NSCLC cells or epidermal growth factor receptor gene (EGFR)-mutant NSCLC cells. Moreover, inhibition of miR-455-3p exhibited the opposite effect. CRNDE bound with miR-455-3p, and HDAC2 was found to be targeted by miR-455-3p. Meanwhile, miR-455-3p downregulation reversed the effect of CRNDE knockdown on NSCLC cell function. Furthermore, miR-455-3p notably inhibited the growth and invasion of NSCLC cells via downregulation of HDAC2. Knockdown of CRNDE attenuated NSCLC progression via modulation of the miR-455-3p/HDAC2 axis. Thus, those findings might provide a novel strategy against NSCLC.

Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases

Diagnosing neuromyelitis optica spectrum disorder (NMOSD) remains a challenge, especially in patients with atypical presentations. Here, we describe two NMOSD patients who initially presented psychiatric symptoms without cortical lesions. This report expands our understanding of the possible presentations of NMOSD. Knowledge of rare initial symptoms may allow timely diagnosis and early therapeutic intervention, preventing more severe attacks affecting the spinal cord or eyes.